Reported Standalone quarterly numbers for GlaxoSmithKline Pharmaceuticals are:Net Sales at Rs 738.02 crore in June 2023 up 1.17% from Rs. 729.46 crore in June 2022.
Quarterly Net Profit at Rs. 130.58 crore in June 2023 up 10.03% from Rs. 118.68 crore in June 2022.
EBITDA stands at Rs. 178.05 crore in June 2023 up 1.33% from Rs. 175.72 crore in June 2022.
GlaxoSmithKline EPS has decreased to Rs. 6.94 in June 2023 from Rs. 7.01 in June 2022.
| GlaxoSmithKline shares closed at 1,401.40 on July 26, 2023 (NSE) and has given 10.96% returns over the last 6 months and -4.11% over the last 12 months. |
| GlaxoSmithKline Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'23 | Mar'23 | Jun'22 | | Net Sales/Income from operations | 738.02 | 782.16 | 729.46 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 738.02 | 782.16 | 729.46 | | EXPENDITURE | | Consumption of Raw Materials | 145.47 | 95.70 | 138.14 | | Purchase of Traded Goods | 174.20 | 177.79 | 271.60 | | Increase/Decrease in Stocks | -44.38 | 69.34 | -136.86 | | Power & Fuel | -- | -- | -- | | Employees Cost | 165.00 | 148.84 | 151.22 | | Depreciation | 16.36 | 17.18 | 15.82 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 156.48 | 123.73 | 157.43 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 124.89 | 149.58 | 132.11 | | Other Income | 36.80 | 27.97 | 27.79 | | P/L Before Int., Excpt. Items & Tax | 161.69 | 177.55 | 159.90 | | Interest | 0.28 | 0.65 | 0.68 | | P/L Before Exceptional Items & Tax | 161.41 | 176.90 | 159.22 | | Exceptional Items | 17.30 | 10.40 | -- | | P/L Before Tax | 178.71 | 187.30 | 159.22 | | Tax | 48.13 | 55.82 | 43.59 | | P/L After Tax from Ordinary Activities | 130.58 | 131.48 | 115.63 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | 3.05 | | Net Profit/(Loss) For the Period | 130.58 | 131.48 | 118.68 | | Equity Share Capital | 169.41 | 169.41 | 169.41 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 6.94 | 7.28 | 7.01 | | Diluted EPS | 7.71 | 7.77 | 7.01 | | EPS After Extra Ordinary | | Basic EPS | 6.94 | 7.28 | 7.01 | | Diluted EPS | 7.71 | 7.77 | 7.01 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
